On February 10, 2021 ENTEROME SA, a clinical-stage biopharmaceutical company focused on the discovery and development of novel microbiome driven therapeutics based on the unrivalled understanding of the gut microbiome’s interaction with the human immune system, reported that the company’s management will participate in the upcoming (virtual) investor events (Press release, Enterome, FEB 10, 2021, View Source;utm_medium=rss&utm_campaign=enterome-presenting-at-upcoming-investor-meetings [SID1234574854]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan Virtual Microbiome Medicines Summit: March 8
H.C. Wainwright Global Life Sciences Conference: March 9-10
Pierre Belichard, Enterome’s CEO, will present the Company and take part in 1-on-1 meetings with institutional investors.

Mr Belichard will also take part in a panel discussion on the Microbiome & Cancer at:

USF Microbiome Virtual Corporate Forum Series, a free-to-register event (click here), on March 10 from 10:00-12:00 EST.